This story was first published in digitalhealth.net
CDF to consider once-a-day pill for ovarian cancer
NICE has invited biopharmaceutical company Tesaro to submit a proposal for including niraparib in the Cancer Drugs Fund (CDF), for treating some types of recurrent ovarian cancer.
According to company estimates, up to 850 women in England and Wales could benefit from this new treatment with late diagnosis often leaving women with this type of cancer with chemotherapy as the only available treatment. Ovarian cancer is one of the most common types of cancer in women.
Niraparib was appraised for the treatment of women with relapsed ovarian, fallopian tube and peritoneal cancer who have had two or more courses of platinum based chemotherapy. Trails have shown that the drug stalled cancer growth by around six to 15.5 months more than placebo, depending on a woman’s genetic profile.
Mirella Marlow, acting director of the centre for health technology evaluation at NICE said: “The outcome for women with ovarian cancer is generally poor, with less than 35 per cent surviving for five years after diagnosis. The inclusion of niraparib in the Cancer Drugs Fund will give women early access to this treatment while uncertainties in the clinical evidence can be addressed through the collection of additional data.”
Latest News
16/02/2024 - 12:56
Hammersmith and Fulham Council has created a new alliance intended to clean dirty air and improve residents' health.
16/02/2024 - 10:44
Two million more GP appointments a month are being delivered for patients compared to the same month before the pandemic as part of the NHS primary care access recovery plan according to new NHS data.
15/02/2024 - 10:26
The Welsh Government has provided innovation funding of £380,000 to support two projects utilising technology in domiciliary care.
15/02/2024 - 10:13
The new Scottish health secretary has met with frontline staff at Queen Elizabeth University Hospital in Glasgow.
14/02/2024 - 10:27
The North East London NHS Foundation Trust (NELFT) has appointed three new Executive Directors to the Trust Board.
Product Features
UK Building Regulations highlight toxic gas and smoke from layers of paint built up over multiple redecorations as a major cause of permanent ill health or death in a building fire.
Their concern rose with discovery the flame retardant paints most widely used paint along escape routes have been ones which to this day counter-productively use emission of heavy toxic gas to smother flames which rapidly spread along walls if layers of paint delaminate in a fire.
Supplier Profiles
Northwich’s Victoria Infirmary (VIN) Community Diagnostic Centre (CDC) has enabled more patients
Adveco, the commercial hot water specialist, announces the launch of live metering of domestic ho
Latest Features
Sarah Greenslade, public affairs and communications officer at the British Parking Association looks at some of the problems and innovations in healthcare parking
It’s easy to assume that the comms team is there to handle press enquiries and the occasional social media storm – but the reality is that strategic communications can make a measurable impact across the entire organisation, from operational to financial, when done properly
